《Couma-Gen研究》的结果反映,根据药物遗传学的研究结果(PG),个体化地调节华法令剂量是可行的。优于预料一个稳定的维持量;比标准方案验血次数少些,调整剂量次数少些。虽然2个具体的基因型小组得出上述结果,增加了研究的信心,PG指导研究还未能达到研究的第一终点:降低国际标准 The results of the Couma-Gen study reflect that it is feasible to dose-regulate warfarin individually, based on studies in pharmacogenetics (PG). Better than expected a stable maintenance dose; less than the number of standard blood tests, adjust the dose less. Although two specific genotyping panels generated the above results, increasing confidence in the study, the PG guidance study has not yet reached the first endpoint of the study: Reducing International Standards